Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 8, 2013, Pages 1317-1327

  Chandran, Parwathy ^a   Gupta, Neha ^a   Retnakumari, Archana Payickattu ^a   Malarvizhi, Giridharan Loghanathan ^a   Keechilat, Pavithran ^a   Nair, Shantikumar ^a   Koyakutty, Manzoor ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cancer kinome; Core shell nanomedicine; Kinase inhibitors; Leukemia; Targeting

Indexed keywords

CANCER KINOME; CORE-SHELL; KINASE INHIBITORS; LEUKEMIA; TARGETING;

ANTIBIOTICS; BLOOD; CELL MEMBRANES; DESIGN; DISEASES; ENZYMES; FUNCTIONAL POLYMERS; MONOCLONAL ANTIBODIES; PROTEINS; SHELLS (STRUCTURES);

MEDICAL NANOTECHNOLOGY;

ALBUMIN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CELL RECEPTOR; CYTARABINE; DAUNORUBICIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NANOMATERIAL; POLYGLACTIN; POLYMER; SORAFENIB; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA CELL; APOPTOSIS; ARTICLE; ASSAY; BLOOD CELL; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; ELECTRON MICROSCOPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LETHALITY; LEUKEMIA CELL; NANOMEDICINE;

CANCER KINOME; CORE-SHELL NANOMEDICINE; KINASE INHIBITORS; LEUKEMIA; TARGETING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; NANOMEDICINE; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYGLACTIN 910; PROTEIN KINASE INHIBITORS; SIALIC ACID BINDING IG-LIKE LECTIN 3; SIROLIMUS; STAT5 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84886444894     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.04.012     Document Type: Article

References (42)

1. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
2. Arora A., Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005, 315:971-979.
3. Knight Z.A., Lin H., Shokat K.M. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010, 10:130-137.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
5. Shipley J.L., Butera J.N. Acute myelogenous leukemia. Exp Hematol 2009, 37:649-658.
6. Roboz G.J. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2011, 2011:43-50.
7. O'Brien S.N., Blijlevens N.M.A., Mahfouz T.H., Anaissie E.J. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program 2003, 438-472.
8. McCubrey J.A., Steelman L.S., Abrams S.L., Bertrand F.E., Ludwig D.E., Bäsecke J., et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008, 22:708-722.
9. Steelman L.S., Abrams S.L., Whelan J., Bertrand F.E., Ludwig D.E., Bäsecke J., et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22:686-707.
10. Birkenkamp K.U., Geugien M., Lemmink H.H., Kruijer W., Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001, 15:1923-1931.
11. Mendoza M.C., Er E.E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011, 36:320-328.
12. Grandage V.L., Gale R.E., Linch D.C., Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005, 19:586-594.
13. Yee K.W.L., Zeng Z., Konopleva M., Verstovsek S., Ravandi F., Ferrajoli A., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006, 12:5165-5173.
14. Borthakur G., Kantarjian H., Ravandi F., Zhang W., Konopleva M., Wright J.J., et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011, 96:62-68.
15. Röllig C., Brandts C., Shaid S., Hentrich M., Krämer A., Junghanß C., et al. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leuk Lymphoma 2012, 53:1062-1067.
16. Atkins M.B., Yasothan U., Kirkpatrick P. Everolimus. Nat Rev Drug Discov 2009, 8:535-536.
17. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844.
18. Rahmani M., Nguyen T.K., Dent P., Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol 2007, 72:788-795.
19. Taussig D.C., Pearce D.J., Simpson C., Rohatiner A.Z., Lister T.A., Kelly G., et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005, 106:4086-4092.
20. Foran J.M. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy. Hematology 2012, 17(Suppl. 1):S137-S140.
21. Bernstein I.D. CD33 as a target for selective ablation of acute myeloid leukemia. Clin Lymphoma 2002, 2(Suppl. 1):S9-S11.
22. van Der Velden V.H., te Marvelde J.G., Hoogeveen P.G., Bernstein I.D., Houtsmuller A.B., Berger M.S., et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001, 97:3197-3204.
23. Walter R.B., Appelbaum F.R., Estey E.H., Bernstein I.D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119:6198-6208.
24. Astete C.E., Sabliov C.M. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 2006, 17:247-289.
25. Manchanda R., Fernandez-Fernandez A., Nagesetti A., McGoron A.J. Preparation and characterization of a polymeric (PLGA) nanoparticulate drug delivery system with simultaneous incorporation of chemotherapeutic and thermo-optical agents. Colloids Surf B Biointerfaces 2010, 75:260-267.
26. Retnakumari A., Setua S., Menon D., Ravindran P., Muhammed H., Pradeep T., et al. Molecular-receptor-specific, non-toxic, near-infrared-emitting Au cluster-protein nanoconjugates for targeted cancer imaging. Nanotechnology 2010, 21:055103.
27. Retnakumari A., Jayasimhan J., Chandran P., Menon D., Nair S., Mony U., et al. CD33 monoclonal antibody conjugated Au cluster nano-bioprobe for targeted flow-cytometric detection of acute myeloid leukaemia. Nanotechnology 2011, 22:285102.
28. Tod M., Mir O., Bancelin N., Coriat R., Thomas-Schoemann A., Taieb F., et al. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res 2011, 28(12):3199-3207.
29. Ruvinsky I., Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006, 31:342-348.
30. Hoshii T., Tadokoro Y., Naka K., Ooshio T., Muraguchi T., Sugiyama N., et al. mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest 2012, 122:2114-2129.
31. Milella M., Kornblau S.M., Estrov Z., Carter B.Z., Lapillonne H., Harris D., et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001, 108:851-859.
32. Blalock W.L., Moye P.W., Chang F., Pearce M., Steelman L.S., McMahon M., et al. Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells. Leukemia 2000, 14:1080-1096.
33. Blalock W.L., Pearce M., Steelman L.S., Franklin R.A., McCarthy S.A., Cherwinski H., et al. A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. Oncogene 2000, 19:526-536.
34. Brady A., Gibson S., Rybicki L., Hsi E., Saunthararajah Y., Sekeres M.A., et al. Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia. Eur J Haematol 2012, 89:288-293.
35. Bunting K.D. STAT5 signaling in normal and pathologic hematopoiesis. Front Biosci 2007, 12:2807-2820.
36. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8:945-954.
37. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
38. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
39. She M., Niu X., Chen X., Li J., Zhou M., He Y., et al. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity. Cancer Lett 2012, 318:173-179.
40. Gores G.J., Kaufmann S.H. Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev 2012, 26:305-311.
41. Pawaskar D.K., Straubinger R.M., Fetterly G.J., Hylander B.H., Repasky E.A., Ma W.W., et al. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemother Pharmacol 2013, [Epub ahead of print].
42. Harzstark A.L., Small E.J., Weinberg V.K., Sun J., Ryan C.J., Lin A.M., et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 2011, 117(18):4194-4200.